Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
57-15-8
Molecular formula
C4H7Cl3O
Molecular weight
177.45 g/mol
Drug class
Halogenated tertiary alcoholpharmaceutical preservative with local anaesthetic properties
Mechanism of action
Exerts antimicrobial preservative activity in aqueous pharmaceutical solutions. At local concentrations it may also produce mild local anaesthetic effects; activity and safety depend on formulation and route.
Indications / reported uses
Used primarily as an antimicrobial preservative in ophthalmic, otic and other pharmaceutical formulations; some historical topical preparations used it as a local anaesthetic ingredient. It should not be assigned a general systemic therapeutic indication.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Chlorobutanol Environmental Risk Assessment (ERA) (the Chlorobutanol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.